tiprankstipranks
Trending News
More News >

Revvity upgraded to Buy from Neutral at UBS

UBS upgraded Revvity (RVTY) to Buy from Neutral with a price target of $115, down from $145. The firm believes Revvity’s growth algorithm could be upside differentiated vs. peers and concerns on China diagnostics are overblown, the analyst tells investors in a research note. Self help and differential exposure shield life sciences from the worst of industry challenges, UBS argues, adding that takeaways from recent doctor diligence on autoimmune diagnostics suggest both strong growth prospects and a greater competitive moat than the firm had appreciated.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue